Protalix BioTherapeutics

Company Overview

Snapshot

Founded in January 1994, Protalix BioTherapeutics operates with 51–200 employees. The company has raised over $159.9 million across 11 funding rounds from 5 investors. In February 2021, Protalix BioTherapeutics completed a public offering, raising approximately $40 million.

Business overview

Protalix BioTherapeutics is a biopharmaceutical company specializing in the development, production, and commercialization of recombinant therapeutic proteins. Leveraging its proprietary ProCellEx plant-cell-based protein expression system, the company aims to create clinically superior versions of therapeutic proteins for established pharmaceutical markets. Its product pipeline includes treatments like Elelyso (taliglucerase alfa for injection), which received FDA approval in May 2012, and other candidates such as PRX-102 and PRX-115. Protalix BioTherapeutics operates within the Health Tech & Life Sciences sector, focusing on Pharma & Medical Biotechnology, specifically Drugs Discovery & Development, and serves the pharmaceutical industry.

Strategic signal

In September 2025, Protalix BioTherapeutics is scheduled to present at the H.C. Wainwright 27th Annual Global Investment Conference, signaling ongoing engagement with the investment community and a continued focus on communicating its strategic direction and pipeline progress. This consistent presence at key investor events indicates the company's commitment to maintaining investor confidence and attracting further capital, despite recent regulatory setbacks concerning Elfabrio's dosing regimen.

Company Intelligence Q&A

What was a significant recent development for Protalix BioTherapeutics regarding its financial standing?

In September 2024, Protalix BioTherapeutics announced the repayment of outstanding senior secured convertible promissory notes, indicating a strengthening of its financial position and a reduction in debt obligations.

What is the company's plan for investor engagement in late 2025?

Protalix BioTherapeutics is scheduled to present at the H.C. Wainwright 27th Annual Global Investment Conference in September 2025 and at the Investor Summit Virtual in September 2025, demonstrating continued efforts to engage with investors and communicate its strategy.

What is the status of Protalix BioTherapeutics' product, Elelyso?

Elelyso (taliglucerase alfa for injection), produced by Protalix BioTherapeutics' ProCellEx system, received FDA approval in May 2012 and subsequent approvals from other regulatory agencies. The product has been licensed to Pfizer.

What was a key partnership for Protalix BioTherapeutics in 2017?

In October 2017, Protalix BioTherapeutics entered into an exclusive ex-US partnership with Chiesi Farmaceutici for the development and commercialization of PRX-102 (pegunigalsidase alfa) for the treatment of Fabry Disease.

What was a notable financial event for Protalix BioTherapeutics in February 2021?

In February 2021, Protalix BioTherapeutics completed a public offering, raising approximately $40 million in gross proceeds.